4D Molecular Therapeutics (FDMT) Stock: Buy, Sell, or Hold?
FDMT - 4D Molecular Therapeutics, Inc. Common Stock
$13.67
-0.17 (-1.23%)
âŧ
5d:
-5.53%
30d:
-8.5%
90d:
+7.47%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When FDMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: FDMT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: FDMT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: FDMT is currently trading at $13.67, which is considered fair relative to its 30-day fair value range of $13.96 to $15.37.
Technical Outlook: Technically, FDMT is in a strong uptrend. The price is currently testing key support at $13.56. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FDMT scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.18 (+106.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FDMT is in a strong uptrend. The price is currently testing key support at $13.56. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: FDMT scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $28.18 (+106.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$13.96 -
$15.37
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (24/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 106.2% below Wall St target ($28.18)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.96 -
$15.37
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$13.56
Resistance Level
$16.23
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.34
Wall Street Target
$28.18
(+106.2%)
Revenue Growth (YoY)
25106.7%
Profit Margin
-194.7%
Share & Embed Analysis
Last updated: October 02, 2026 11:00 PM ET
Data refreshes hourly during market hours. Next update: 12:00 AM
Data refreshes hourly during market hours. Next update: 12:00 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FDMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
